MedTrace Logo

Study to Evaluate the Efficacy and Safety of P-3074 Topical Solution in the Treatment of Androgenetic Alopecia

NCT03004469 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 458

Last updated 2019-06-20

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to confirm the clinical efficacy and the safety of P-3074 in participants with androgenetic alopecia.

Conditions

  • Alopecia, Androgenetic

Interventions

DRUG

P-3074

DRUG

Finasteride

DRUG

P-3074 Vehicle

DRUG

Finasteride Placebo

Sponsors & Collaborators

  • Polichem S.A.

    lead INDUSTRY

Principal Investigators

  • Eric Massana, MD · Almirall, S.A.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-08-02
Primary Completion
2018-03-05
Completion
2018-03-05

Countries

  • Belgium
  • Germany
  • Hungary
  • Russia
  • Spain

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03004469 on ClinicalTrials.gov